Deregulated activation of matriptase in breast cancer cells

Clinical and Experimental Metastasis

Volumn 19, Issue 7, 2002, Pages 639-649

  Benaud, Christelle M ^a   Oberst, Michael ^a   Dickson, Robert B ^a   Lin, Chen Yong ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Actin filament; Breast cancer cells; EGF; HAI 1; Mammary epithelial cells; Matriptase; Shingosine 1 phosphate

Indexed keywords

EPIDERMAL GROWTH FACTOR; MATRIPTASE; PROTEIN INHIBITOR; SCATTER FACTOR; SERINE PROTEINASE; UNCLASSIFIED DRUG; UROKINASE;

ACTIN FILAMENT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER GROWTH; CELL MOTILITY; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; REGULATORY MECHANISM; TUMOR VASCULARIZATION;

ACTINS; BREAST; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL MEMBRANE; CYTOSKELETON; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MEMBRANE GLYCOPROTEINS; SERINE ENDOPEPTIDASES; SPHINGOSINE; TRYPSIN; TUMOR CELLS, CULTURED;

EID: 0036459128     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020985632550     Document Type: Article

References (44)

1. Lin CY, Anders J, Johnson M et al. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999; 274: 18231-6.
2. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999; 96: 11054-61.
3. Tanimoto H. Underwood LJ, Wang Y et al. Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001; 22: 104-14.
4. Kim MG, Chen C, Lyu MS et al. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999; 49: 420-8.
5. Hooper JD, Clements JA, Quigley JP et al. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857-60.
6. Oberst M, Anders J, Xie B et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158: 1301-11.
7. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
8. Takeuchi T, Harris JL, Huang W et al. Cellular localization of membrane-type serine protease 1 and identification of protease activated receptor-2 and single-chain urokinase-type plasiminigen activator as substrates. J Biol Chem 2000; 275: 26333-42.
9. Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 2001; 268: 1439-47.
10. Benaud C, Oberst M, Hobson JP et al. Sphingosine-l-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem 2002; 277: 10539-46.
11. Lin CY, Wang JK. Torri J et al. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. J Biol Chem 1997; 272: 9147-52.
12. Lin CY, Anders J, Johnson M et al. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-42.
13. Shi YE, Torri J, Yieh L et al. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 1993; 53: 1409-15.
14. Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 6370-6.
15. Kawaguchi T, Qin L, Shimomura T et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 27558-64.
16. Wells A. Tumor invasion: Role of growth factor-induced cell motility. Adv Cancer Res 2000; 78: 31-101.
17. Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996; 67: 423-9.
18. Holst-Hansen C, Johannessen B, Hoyer-Hansen G et al. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; 14: 297-307.
19. Tsunezuka Y, Kinoh H, Takino T et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996; 56: 5678-83.
20. Powell WC, Knox JD, Navre M et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 417-22.
21. Look MP, Foekens JA. Clinical relevance of the urokinase plasminogeri activator system in breast cancer. APMIS 1999; 107: 150-9.
22. Barsky SH, Siegal GP, Jannotta F et al. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983; 49: 140-7.
23. De Clerck YA, Perez N, Shimada H, Boone TC et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-8.
24. Imren S, Kohn DB, Shimada H, Blavier L et al. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891-5.
25. Albini A, Melchiori A, Santi L et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775-9.
26. Khokha R, Zimmer MJ, Graham CH et al. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992; 84: 1017-22.
27. Lee MJ, Thangada S, Claffey KP et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301-12.
28. Takaishi K, Sasaki T. Kotani H et al. Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells. J Cell Biol 1997; 139: 1047-59.
29. Braga VM, Machesky LM, Hall A et al. The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts. J Cell Biol 1997; 137: 1421-31.
30. Sahai E, Marshall CJ. Rho-GTPase and Cancer. Nature Rev Cancer 2002; 2: 133-42.
31. Wang F, Van Brocklyn JR, Edsall L et al. Sphingosine-l-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Cancer Res 1999; 59: 6185-91.
32. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81: 682-7.
33. van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000; 2: 418-25.
34. Laug WE, Cao XR, Yu YB et al. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993; 53: 6051-7.
35. Menendez-Arias L, Risco C. Oroszlan S et al. Isolation and characterization of alpha 2-macroglobulin-protease complexes from purified mouse mammary tumor virus and culture supernatants from virus-infected cell lines. J Biol Chem 1992; 267: 11392-8.
36. Soff GA, Sanderowitz J, Gately S et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96: 2593-600.
37. Wang M, Liu YE, Greene J et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997; 14: 2767-74.
38. Knoop A, Andreasen PA, Andersen JA et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77: 932-40.
39. Foekens JA, Peters HA, Look MP et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-43.
40. Foekens JA, Schmitt M, van Putten WL et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648-58.
41. McCarthy K, Maguire T, McGreal G et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999; 84: 44-8.
42. Remacle A, McCarthy K, Noel A et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000; 89: 118-21.
43. Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-8.
44. Kataoka H, Shimomura T, Kawagachi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40453-62.